Skip to main content
. Author manuscript; available in PMC: 2014 May 27.
Published in final edited form as: Cancer Gene Ther. 2014 Jan 17;21(1):38–44. doi: 10.1038/cgt.2013.81

Figure 2.

Figure 2

The survival benefit of Ad.mIL12 gene therapy is associated with alterations in the myeloid-derived suppressor cell (MDSC) population. (a) Intratumoral delivery of Ad.mIL12 1 week after GL261 mouse glioma establishment results in tumor clearance and long-term survivors. (b) Flow cytometry shows that interleukin-12 (IL-12) immunotherapy reduces MDSCs’ presence in the brains of glioma-bearing mice (representative flow plot depicted below the graph). (c–e) Phenotypic changes of MDSCs after IL-12 immunotherapy. (c) Flow cytometry detects increased expression of antigen-presenting and costimulatory molecules such as major histocompatibiltiy complex (MHC) class II and CD80 (representative flow plot depicted below the graph). Quantitative reverse transcription-polymerase chain reaction (RT-PCR) shows reduction of mRNA transcripts for immunosuppressive factors, such as arginase-1 (d) and inducible nitric oxide synthase (iNOS) (e). mRNA transcription was expressed as the percent of control-treated group. *P<0.05.